Unknown

Dataset Information

0

A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia.


ABSTRACT: Hepcidin plays a central role in iron homeostasis and erythropoiesis. Neutralizing hepcidin with a monoclonal antibody (mAb) may prevent ferroportin internalization, restore iron efflux from cells, and allow transferrin-mediated iron transport to the bone marrow. This multicenter, phase 1 study evaluated the safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of a fully humanized mAb (LY2787106) with high affinity for hepcidin in cancer patients with anemia.Thirty-three patients with hepcidin levels ?5 ng/mL received LY2787106 either every 3 weeks (19 patients, dose range 0.3-10 mg/kg) (part A) or weekly (14 patients, dose 10 mg/kg) (part B). LY2787106 PK/PD markers of iron and hematology biology were measured.LY2787106 clearance (32 mL/h) and volume of distribution (7.7 L) were independent of dose and time, leading to a dose-proportional increase in concentration with dose. Consistent dose-dependent increases in serum iron, and transferrin saturation were seen at the 3 and 10 mg/kg dose levels, typically peaking within 24 h after LY2787106 administration and returning to baseline by day 8.Our findings indicate that LY2787106 was well tolerated in cancer patients with anemia and that targeting the hepcidin-ferroportin pathway by neutralizing hepcidin resulted in transient iron mobilization, thus supporting the role of hepcidin in iron regulation.ClinicalTrial.gov, NCT01340976.

SUBMITTER: Vadhan-Raj S 

PROVIDER: S-EPMC5361694 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia.

Vadhan-Raj Saroj S   Abonour Rafat R   Goldman Jonathan W JW   Smith David A DA   Slapak Christopher A CA   Ilaria Robert L RL   Tiu Ramon V RV   Wang Xuejing X   Callies Sophie S   Cox Joanne J   Tuttle Jay L JL   Lau Yiu-Keung YK   Roeland Eric J EJ  

Journal of hematology & oncology 20170321 1


<h4>Background</h4>Hepcidin plays a central role in iron homeostasis and erythropoiesis. Neutralizing hepcidin with a monoclonal antibody (mAb) may prevent ferroportin internalization, restore iron efflux from cells, and allow transferrin-mediated iron transport to the bone marrow. This multicenter, phase 1 study evaluated the safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of a fully humanized mAb (LY2787106) with high affinity for hepcidin in cancer patients with anemia.<h4>  ...[more]

Similar Datasets

| S-EPMC6878771 | biostudies-literature
| S-EPMC8488777 | biostudies-literature
| S-EPMC4623385 | biostudies-literature
| S-EPMC4612616 | biostudies-literature
| S-EPMC10465702 | biostudies-literature
| S-EPMC9434412 | biostudies-literature
| S-EPMC5418443 | biostudies-literature
| S-EPMC4795808 | biostudies-literature
| S-EPMC6246722 | biostudies-literature
| S-EPMC3432706 | biostudies-literature